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1. Introduction 
Mesothelin (MSLN) is a glycosylphosphatidylinositol (GPI)-anchored cell surface glycoprotein 
and differentiation antigen. MSLN gets its name from typically limited expression in the 
mesothelial lining of the pleural cavity, where it was first identified in 1996 by Chang and 
Pastan1. The human MSLN gene (localized to 16p21)2 encodes a 71-kDa precursor protein that 
is cleaved by furin-like proteinases to produce an amino-terminal 31 kDa soluble fragment, 
termed the megakaryocyte-potentiating factor (MPF), which is released to the extracellular 
fluid, and a carboxy-terminal 40 kDa membrane-bound fragment1,3,4. 
The normal function of MSLN has remained elusive. Following the initial report of 
megakaryocyte colony-forming activity5, a mutant mouse model generated by homologous 
recombination showed that platelet numbers in both wild-type and MSLN null mice, were 
not changed, which suggested that MSLN is not required for megakaryocyte growth and 
differentiation in vivo6. These mice also showed no discernable phenotype, indicating that 
either MSLN does not play a significant role in vivo or that other molecules may be filling in 
for MSLN by playing a similar role in normal tissues. MSLN is predicted to have a 
superhelical structure made of ARM-type helical repeats, and is thereby predicted to 
function as superhelical lectins that bind the extracellular carbohydrate moiety of 
glycoproteins7. Supporting a potential role in cell-to-cell adhesion, it has been shown that 
MSLN interacts with mucin MUC16 to enhance cell-cell binding, which can play a role in 
leading to peritoneal metastatic dissemination of tumors8. 
Where the importance of MSLN is evident in the progression of cancers. MSLN is 
overexpressed in a variety of cancers, including mesotheliomas, stomach, and endometrial 
cancers, as well as in squamous cell carcinomas of the esophagus, lung, and cervix9,10. In 
addition, several studies have reported the overexpression of MSLN in virtually all human 
pancreatic ductal adenocarcinomas11. In tumors, MSLN may function as a mediator of cell 
survival under anchorage-independent conditions, where it facilitates anchorage-
independent growth and confers resistance to anoikis12.  
2. Mesothelin in pancreatic cancers 
Despite the fact that it is only the tenth most common type of cancer and accounts for only 
6% of new cancer cases in North America, pancreatic cancer is the deadliest cancer, with the 
www.intechopen.com
 Pancreatic Cancer – Molecular Mechanism and Targets 
 
252 
worst prognosis of all solid tumors13. Due to its highly aggressive nature characterized by 
invasive growth and early metastasis, and compounded by late diagnosis and lack of 
effective therapies for treatment, pancreatic cancer remains the fourth leading cause of 
cancer-related deaths, 35,000 deaths from 42,000 new cases per year3,14 and a 5 year survival 
rate of less than 5%13,14.  
In addition to its role in other cancers, MSLN is increasingly becoming established as a key 
factor in human pancreatic adenocarcinomas. The soluble fragment of MSLN, MPF, was first 
detected in the supernatant of the HPC-Y5 human pancreatic cell line in 1994 5. In fact, HPC-
Y5 had the highest MPF activity of 64 cancer cell lines tested, implicating MPF as an 
important factor in pancreatic anomalies. The latest research confirms the MPF is in fact 
responsible for increased phosphorylation of ERK1/2, leading to a decreased rate of cell 
death and an increase in cell number15. 
MSLN expression has since been assessed in pancreatic cancers, where it is found to be 
overexpressed in a majority of pancreatic ductal adenocarcinomas4,9,16, with little expression 
in normal pancreas and chronic pancreatitis11. In their studies, for instance, Argani et al. 
used serial analysis of gene expression (SAGE) as well as in situ hybridization, RT-PCR, and 
immunohistochemistry to show that MSLN is consistently overexpressed in 60 of 60 
pancreatic tumors. Meanwhile, MSLN does not seem to be expressed in normal pancreatic 
tissues 4,17,18. Recently, for instance, Glass et al. showed that MSLN 24 of 42 (57%) 
adenocarcinomas stained for MSLN, while only 0 of 16 non-carcinomas (0%) did so19.  
Exactly what the molecular mechanisms are which give rise to MSLN overexpression are 
not well documented. However, a recent study attributed MSLN overexpression in 
pancreatic cancers to an upstream enhancer element containing a transcription enhancer 
factor (TEF-1) dependent MCAT motif termed Canscript2, although the presence of this 
factor was required but not sufficient for MSLN expression. The oncogenic transcription co-
factor YAP1, normally phosphorylated and inactivated by the Hippo-YAP1 pathway, has 
been implicated in the activation of MSLN expression through the regulation of Canscript 
activity. Knocking down YAP1 expression in HeLa cells dramatically reduced endogenous 
MSLN expression and suppressed Canscript reporter activity; yet overexpression of YAP1 
in HEK293 cells did not turn on MSLN expression, indicating that YAP1 may be necessary 
but not sufficient for MSLN overexpression20. Another study analyzed the methylation state 
of several pancreatic cancer-associated genes, and found that MSLN was hypomethylated in 
adenocarcinoma compared to its methylated state in normal pancreatic tissues, indicating an 
epigenetic event trigger is involved in MSLN overexpression21.  
Pancreatic cancer studies have revealed roles for MSLN in increasing aggressiveness of 
tumor cells, including enhancement of proliferation and migration. Li et al. found that 
overexpression of MSLN is also associated with an increased S-phase cell population in a 
cell cycle analysis. This resulted in a 90% increase in proliferation for MIA-PaCa2 cells 
overexpressing MSLN compared to vector controls16. Subsequent studies by Bharadwaj et al. 
elucidated a mechanism through which MSLN promotes proliferation of pancreatic cancer 
cells through alteration of Cyclin E as a result of constitutive activation of Signal Transducer 
and Activator of Transcription protein 3 (STAT3)3. Bharadwaj et al. have further shown that 
MSLN overexpression results in upregulation of growth/survival pathways through 
autocrine production of growth factors such as IL-622. MSLN also induces in an increase in 
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NF-B activation which leads to resistance to TNF-α-induced apoptosis23, indicating a 
mechanism through which MSLN may help to increase survival of tumor cells in the highly 
inflammatory milieu evident in pancreatic cancer through Akt/PI3K/NF-B Activation and 
IL-6 overexpression. MSLN overexpression results in secretion of high levels of IL-6, which 
could in turn be responsible for the cells’ increased viability and proliferation under serum-
reduced conditions through a IL-6/soluble IL-6R (sIL-6R) trans-signaling mechanism and 
the induction of the IL-6-STAT3 pathway3,22. 
MSLN overexpression has also been associated with increased metastatic potential in 
pancreatic cancers. In vitro experiments showed that MSLN increases pancreatic cancer cell 
migration by 300%, while in vivo results showed and increase in local and liver metastases 
following orthotopic injection, with control cells without MSLN expression showing no 
metastases16. Cancer antigen-125 (CA125), the circulating antigen encoded by the MUC16 
gene, has been identified as a marker for differential diagnosis of pancreatic mass lesions 
with an 88.2% positive predictive value for diagnosis of pancreatic tumors24. Taking into 
account that the high affinity of mesothelin-CA125 interaction might be the cause of 
intracavitary tumor metastasis8,25, a recent study by Einama et al. determined that co-
expression of these two factors plays a significant role in the acquisition of aggressive 
clinical behavior of pancreatic tumors, finding that co-expression of MSLN and CA125 
correlated with unfavorable patient survival outcome 25. 
3. Advances in diagnosis and treatment of mesothelin-overexpressing 
pancreatic cancers 
MSLN is an attractive candidate for targeted therapy given its limited expression on normal 
tissues and high expression in tumors and the fact that it is expressed on the surface of cells. 
Immunostaining against MSLN has been demonstrated to be an effective adjunct to cytology 
for diagnosis of pancreatic adenocarcinoma26, with a 90% accuracy rate in diagnosing 
pancreatic malignancies. In addition, the release of the MPF from the cell surface following 
furin cleavage makes it an attractive target for diagnostic detection.  
Elevated circulating MSLN levels have been detected in patients with pancreatic disease27. 
Using ELISA, 73 of 74 (99%) patients with pancreatic adenocarcinoma were found to have 
elevated circulating levels of MSLN compared with none of 5 healthy controls27. Other 
approaches, including using multiplexed Proximity Ligation Assay (PLA) have been used to 
effectively detect levels of mesothelin-MUC16 complex in serum and plasma levels28. MSLN 
has also been used as a biomarker to test the efficacy of new technologies for early, 
minimally invasive diagnosis of pancreatic adenocarcinoma. In a study involving minimally 
invasive fine needle aspirations MSLN has helped to differentiate pancreatic 
adenocarcinomas from chronic pancreatitis with near 100% accuracy29. Another study 
utilized acoustic wave device-based immunosensors in molecular cancer biomarker 
detection in real-time, and effectively identified MSLN expression in three different 
pancreatic cancer cell supernatants, although further study is needed with this technology to 
determine its effectiveness in patient tissues30. 
Most recently, ELISA has been used not just to test for MSLN circulation in patients with 
advanced tumors, but for attempted early detection of pancreatic anomalies. A pancreatic 
ductal carcinoma transgenic animal model was established in rats using a Cre/loxP 
www.intechopen.com
 Pancreatic Cancer – Molecular Mechanism and Targets 
 
254 
controlled human Kras oncogene 13. Using this system, Fukamachi et al. demonstrated that 
the rat homolog of human MSLN, Erc (expressed in renal carcinoma), could be detected in 
the serum of pre-symptomatic, pre-malignant pancreas lesions, opening the door to 
potential early diagnosis of mesothelin-induced pancreatic malignancies, as well as testing 
of early stage chemotherapeutic intervention to prevent progression of malignancies.  
Potential treatments focusing on MSLN are already undergoing clinical trials. One example 
is use of a mouse-human chimeric antibody (MORAb-009), an IgG1kappa monoclonal 
antibody with an affinity of 1.5 nM for human MSLN containing the murine SS1 Fv for 
MSLN, which is currently being examined in a Phase II clinical trial31,32. This antibody 
prevents adhesion of mesothelin-bearing tumor cells to MUC16 positive cells and also elicits 
cell-mediated cytotoxicity on mesothelin-bearing tumor cells. A newer study using phage 
display has shown successful isolation of HN1, a human scFv, which recognizes a 
conformation-sensitive epitope of MSLN on cancer cells and promotes apoptosis by acting 
as an immunotoxin31. While this particular study focused on ovarian cancer treatment, it 
stands to reason that pancreatic cancer would make an effective target for future treatments 
with this antibody. MSLN has also been used as a targeting factor for pancreatic tumors in 
conjunction with quantum dot (QD) technology. QDs are semi-conductor nanocrystals 
which, when encapsulated in carboxyl-functionalized amphiphilic polymers form stable, 
micelle-like structures which form a potential platform for visualization and drug delivery 
to tumors33. Ding et al. conjugated MSLN-specific Ab to QD micelles and used them for 
effective targeted delivery to pancreatic cancer sites in vitro and in vivo33. The high level of 
overexpression of MSLN in pancreatic cancer cells and tumors compared to normal tissues 
allowed for selective targeting of QDs, indicating the potential of MSLN-targeted QDs or 
other MSLN-conjugated vehicles to serve as agents for tumor diagnosis, imaging, and 
treatment through drug delivery. 
Another approach for MSLN focused therapy comes from studies involving SS1P 
(SS1(dsFv)PE38), a recombinant anti-mesothelin immunotoxin. SS1P was developed 
consisting of an anti-mesothelin Fv (SS1) fused to PE38, a 38-kDa portion of Pseudomonas 
exotoxin A34,35, which kills cells upon internalization following binding to MSLN on the cell 
surface. A phase I study was conducted involving 34 patients, 2 of which had pancreatic 
adenocarcinoma35. The patients tolerated the doses given, indicating a potential for 
progressing to additional studies. Although results were encouraging in patients with 
ovarian cancer or mesotheliomas, no response was seen in the 2 pancreatic cancer patients. 
A second Phase I trial, this time involving continuous infusion of SS1P, was more recently 
conducted36 to measure toxicity tolerance, also with promising results. Newer studies by the 
same group are currently examining methods for improving the efficacy of SS1P therapy by 
combining treatement with Taxol, which appears to limit the binding of SS1P with shed 
MSLN in the extracellular fluid rather than on the cell surface, thereby increasing the 
effectiveness of SS1P internalization and the killing of tumor cells37. Yet another toxin 
insertion approach used a a biodegradable nanoparticulate delivery system targeted 
specifically to mesothelin-overxpressing cell lines to deliver diphtheria toxin DNA, which 
effectively inhibited protein translation of targeted cells in vitro38.  
Finally, approaches using pancreatic cancer vaccines show that MSLN has great potential as 
an immunotherapeutic targets10,39. Johnston et al. showed that mesothelin-specific T cells can 
be induced in patients with pancreatic cancer. Their results indicated that mesothelin-
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specific CD4+ and CD8+ T cells were generated from peripheral blood lymphocytes of 50% 
of patients with pancreatic cancer, up from only 20% of healthy individuals27, and another 
study showed consistent induction of CD8+ T cell responses to multiple MSLN epitopes in a 
small number of patients40. A study by Yokokawa et al. sought to define additional MSLN 
epitotpes capable of more efficiently activating T cells to lyse tumors10. Jaffee et al. carried 
out a phase I trial in patients with surgically resected adenocarcinoma of the pancreas was 
conducted using an allogeneic granulocyte-macrophage colony-stimulating factor (GM-
CSF)-secreting tumor vaccines39. In a phase II trial, these results were confirmed through 
induction of mesothelin-specific CD8+ T cell responses following exposure to different 
MSLN epitopes, leading to a correlation of the posttreatment induction of mesothelin-
specific T cell responses with improved overall response 41. 
The latest attempts at immunotherapy with MSLN involved vaccination with virus-like 
particles (VLPs) to induce protective antiviral immune responses against MSLN, yielding 
promising results. Li et al. investigated the effect and mechanism of chimeric VLPs that 
contain human MSLN (VLP-hMSLN) as a candidate vaccine for controlling pancreatic 
cancer progression in an orthotopic pancreatic cancer mouse model16. In the study, VLP-
hMSLN vaccination inhibited tumor progression in C57BL/6J mice, and increased 
mesothelin-specific antibodies and CTL activity and decreased regulatory T cells, resulting 
in reduced tumor progression and prolonged survival. Most recently, dendritic cells 
transduced with full-length MSLN cDNA-encoding adenoviral vectors have been shown to 
elicit mesothelin-specific cytotoxicity against pancreatic cancer cells in vitro, through 
activation of both CD8+ T cells and CD4+ helper T cells42, suggesting the therapeutic 
potential of using MSLN-targeted DC vaccines in future clinical applications.  
4. Conclusion 
MSLN is an important molecule overexpressed in a variety of cancerous human 
malignancies, and in particular has been identified as a biomarker of pancreatic cancers. The 
high expression of MSLN in pancreatic tumors compared with its limited expression in 
normal tissues makes it an interesting candidate for targeted therapies and diagnostic 
screening. In addition, MSLN has been shown to play important roles in proliferation, 
survival, and metastatic potential of pancreatic tumors where it is overexpressed. While 
much progress has been made in understanding the molecular mechanisms that give rise to 
MSLN-associated pancreatic cancer pathogenesis, further studies are needed to truly 
elucidate the functions and effects of this molecule with regards to what still remains the 
deadliest of human cancers.  
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